Psychedelic drug reviews to speed up as Trump orders ibogaine assessments for medical research

President Donald Trump directed the administration to speed up reviews of some psychedelic drugs, including ibogaine. The move aimed to support medical research and ease some restrictions. Ibogaine stayed banned under the strictest federal drug category. Even so, supporters said it could help severe depression and other hard cases.

Representative image

Trump signed an executive order and linked it to people with serious symptoms. "Todays order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life,\" Trump said. Trump also promised faster access to possible treatments. \"If these turn out to be as good as people are saying, its going to have a tremendous impact,\" Trump said.

Ibogaine executive order and FDA review changes

The Food and Drug Administration planned to issue national priority vouchers next week for three psychedelics. FDA Commissioner Marty Makary said the vouchers could speed approvals for drugs matching national priorities. The agency said review times could drop from months to weeks. It marked the first time this fast track was offered for psychedelics.

The FDA also moved to support the first human trials of ibogaine in the US. No psychedelic had been approved in the United States at the time. Still, large trials were studying psilocybin, MDMA and LSD. These drugs remained illegal as Schedule I substances, alongside heroin. Oregon and Colorado had legalised psilocybin therapy.

Ibogaine safety risks and research hurdles

Some researchers and advocates were surprised by Trump’s action because of ibogaine’s risks. Ibogaine can trigger dangerous heart problems in some cases. The National Institutes of Health funded research in the 1990s, then stopped. The work ended due to ibogaine’s cardiovascular toxicity.

\"Its been incredibly difficult to study ibogaine in the US because of its known cardiotoxicity,\" said Frederick Barrett, director of the Johns Hopkins Centre for Psychedelic and Consciousness Research. \"If the executive order can pave the way for doing objective, scientific research with this compound, it would help us understand whether it is truly a better psychedelic therapy than others.\"

Medical literature linked ibogaine to irregular heart rhythms and more than 30 deaths. The Multidisciplinary Association for Psychedelic Studies reported that figure. The nonprofit had also done early studies in patients outside the US. Clinics that use ibogaine often track heart readings during dosing. Many also keep emergency medical equipment nearby.

Ibogaine veterans, Texas funding, and political support

Veteran groups and psychedelic advocates said ibogaine may help PTSD and opioid addiction. The drug is made from a shrub native to West Africa. It was first used by the Bwiti religion in places like Gabon. In recent years, US veterans travelled to clinics in Mexico for treatment. Some reported benefits after receiving it.

Trump’s announcement followed pledges by Health Secretary Robert F Kennedy Jr and other officials. The issue drew rare support across party lines. Conservative podcaster Joe Rogan and former Navy SEAL Marcus Luttrell joined Trump in the Oval Office. Luttrell’s memoir inspired the film Lone Survivor, based on a mission in Afghanistan.

Rogan said: \"Sounds great. Do you want FDA approval? Lets do it.\" Rogan said the message came after sending Trump information on ibogaine. Luttrell told Trump: \"Youre going to save a lot of lives through it.\" Luttrell added: \"It absolutely changed my life for the better.\"

In Texas, support from veterans groups and former Gov Rick Perry helped drive state action. A law last year set aside $50 million for ibogaine research. Perry co-founded Americans for Ibogaine and spoke about the drug on Rogan’s podcast. It was Perry’s second time discussing ibogaine there in two years. Perry argued for lower federal limits.

Ismail Lourido Ali, co-executive director of the Multidisciplinary Association for Psychedelic Studies, said other states might copy Texas. \"The stigma around Schedule I drugs is significant,\" Ali said. \"It feels like this would give pretty substantial cover for Republican governors and legislatures to step into the ring in terms of funding research programs at their universities.\"

Ibogaine clinics in Mexico and cost details

Owners of ibogaine clinics said the executive order would not change access quickly. \"There will be no insurance coverage, it will still be considered unapproved and non-covered care,\" said Tom Feegel of Beond Ibogaine, which operates in Cancun. Feegel also said: \"But what it does mean is that ibogaine shifts from being fringe and underground to being federally acknowledged.\"

Feegel said the clinic treated 2,000 people with ibogaine last year. The cost ranged between USD 15,000 and USD 20,000 per person. The company also provided free treatment for about 100 veterans. Patients often travelled from the US to receive the drug. Clinics typically tried to reduce medical risks during care.

One recent study by US researchers reported improvements in veteran symptoms after ibogaine. The Stanford University study enrolled 30 veterans treated in Mexico. It did not include a placebo group for comparison. Researchers called placebo controls important for strong evidence. Patients received ibogaine mixed with magnesium to reduce heart risks.

Trump’s order set a faster federal process for reviewing certain psychedelics, including ibogaine. Supporters pointed to reports from veterans and to emerging research results. At the same time, scientists and clinicians stressed known cardiac dangers and past funding cuts. The next steps included FDA vouchers and efforts to begin US trials.

With inputs from PTI